Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Open-label Phase II Trial of Adjunctive Treatment With Ketamine Hydrochloride Prolonged-Release Tablets (KET01) During the Initiation of Antidepressant Therapy in Major Depressive Disorder

NCT07396272 is registered in ClinicalTrials.gov with Daniel Lindqvist as lead sponsor.

NCT NCT07396272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07396272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Open-label Phase II Trial of Adjunctive Treatment With Ketamine Hydrochloride Prolonged-Release Tablets (KET01) During the Initiation of Antidepressant Therapy in Major Depressive Disorder
Lead sponsor
Daniel Lindqvist
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 13, 2026
Completion date
October 1, 2026
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)